LGT Capital Partners LTD. Raises Stock Position in Agilent Technologies, Inc. $A

LGT Capital Partners LTD. increased its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 4.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 803,898 shares of the medical research company’s stock after buying an additional 35,646 shares during the period. Agilent Technologies accounts for about 4.2% of LGT Capital Partners LTD.’s investment portfolio, making the stock its 6th biggest holding. LGT Capital Partners LTD.’s holdings in Agilent Technologies were worth $94,868,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of A. Massachusetts Financial Services Co. MA lifted its stake in shares of Agilent Technologies by 10.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company’s stock valued at $1,560,964,000 after purchasing an additional 1,273,994 shares during the period. Generation Investment Management LLP lifted its stake in Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock valued at $582,976,000 after buying an additional 824,243 shares during the period. M&G PLC boosted its holdings in Agilent Technologies by 255.2% during the second quarter. M&G PLC now owns 893,121 shares of the medical research company’s stock worth $105,388,000 after buying an additional 641,698 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Agilent Technologies by 18.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock worth $448,748,000 after buying an additional 604,124 shares during the period. Finally, Mackenzie Financial Corp increased its stake in shares of Agilent Technologies by 141.5% in the 1st quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock valued at $109,481,000 after acquiring an additional 548,344 shares during the last quarter. 87.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on A. Rothschild & Co Redburn initiated coverage on shares of Agilent Technologies in a research note on Wednesday, October 8th. They set a “buy” rating and a $165.00 price objective on the stock. Wells Fargo & Company increased their target price on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, September 15th. UBS Group raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and boosted their price target for the company from $130.00 to $170.00 in a report on Wednesday, October 8th. JPMorgan Chase & Co. raised their price objective on Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Finally, Barclays boosted their target price on Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $149.62.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 12,490 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total value of $1,873,500.00. Following the sale, the chief executive officer directly owned 33,448 shares in the company, valued at $5,017,200. This trade represents a 27.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is owned by corporate insiders.

Agilent Technologies Trading Up 0.0%

A opened at $146.90 on Friday. The stock has a market capitalization of $41.65 billion, a P/E ratio of 34.48, a P/E/G ratio of 4.67 and a beta of 1.29. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The firm’s fifty day simple moving average is $137.63 and its 200 day simple moving average is $123.77.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter last year, the business posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, research analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th were given a dividend of $0.248 per share. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a yield of 0.7%. Agilent Technologies’s dividend payout ratio is 23.24%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.